Verastem (VSTM) Depreciation Expense (2024 - 2025)
Verastem's quarterly Depreciation Expense came in at $18000.0 in Q4 2025, up 157.14% year-on-year from $7000.0 in Q4 2024, and up 800.0% quarter-over-quarter from $2000.0 in Q3 2025.
Verastem has reported Depreciation Expense for 2 years, with the latest figure at $18000.0 in Q4 2025.
- For the quarter ending Q4 2025, Depreciation Expense rose 157.14% year-over-year to $18000.0; the trailing twelve-month figure through Dec 2025 stood at $30000.0 (up 20.0% YoY), and the FY2025 full-year result was $30000.0, up 15.38% from the prior year.
- Depreciation Expense for Q4 2025 stood at $18000.0, up from $2000.0 in the prior quarter.
- The five-year high for Depreciation Expense was $18000.0 in Q4 2025, with the low at $2000.0 in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | - |
| 10 | Verastem | 425.60 Mn | 243.93 Mn | 15.90 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 18,000.00 |
| Sep 30, 2025 | 2,000.00 |
| Mar 31, 2025 | 10,000.00 |
| Dec 31, 2024 | 7,000.00 |
| Sep 30, 2024 | 7,000.00 |
| Jun 30, 2024 | 5,000.00 |
| Mar 31, 2024 | 6,000.00 |